BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 20484893)

  • 1. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
    Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulatory T cells in kidney transplant recipients].
    Libetta C; Portalupi V; Margiotta E; Sepe V; Canevari M; Meloni F; Morosini M; Dal Canton A
    G Ital Nefrol; 2009; 26 Suppl 45():S54-7. PubMed ID: 19382095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical rejection and persistent immune regulation in kidney transplant patients.
    Hendrikx TK; Klepper M; Ijzermans J; Weimar W; Baan CC
    Transpl Immunol; 2009 Jul; 21(3):129-35. PubMed ID: 19398001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.
    Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V
    Front Immunol; 2021; 12():716559. PubMed ID: 34335631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus vs cyclosporine after induction with basiliximab does not promote regulatory T cell expansion in de novo kidney transplantation: Results from a single-center randomized trial.
    Libetta C; Esposito P; Gregorini M; Margiotta E; Martinelli C; Borettaz I; Canevari M; Rampino T; Ticozzelli E; Abelli M; Meloni F; Dal Canton A
    Transpl Immunol; 2015 Oct; 33(2):117-24. PubMed ID: 26220254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.
    Krystufkova E; Sekerkova A; Striz I; Brabcova I; Girmanova E; Viklicky O
    Nephrol Dial Transplant; 2012 Jun; 27(6):2576-82. PubMed ID: 22167587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors.
    Mittal SK; Sharma RK; Gupta A; Naik S
    Transplantation; 2009 Aug; 88(3):435-41. PubMed ID: 19667950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.
    Hoerning A; Köhler S; Jun C; Lu J; Fu J; Tebbe B; Dolff S; Feldkamp T; Kribben A; Hoyer PF; Witzke O
    Clin Exp Immunol; 2012 May; 168(2):251-9. PubMed ID: 22471287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors.
    Meloni F; Morosini M; Solari N; Bini F; Vitulo P; Arbustini E; Pellegrini C; Fietta AM
    Int Immunopharmacol; 2006 Dec; 6(13-14):2002-10. PubMed ID: 17161354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripherally circulating CD4⁺ FOXP3⁺ CXCR3⁺ T regulatory cells correlate with renal allograft function.
    Hoerning A; Köhler S; Jun C; Tebbe B; Fu J; Menke J; Wilde B; Dolff S; Feldkamp T; Briscoe DM; Kribben A; Hoyer PF; Witzke O
    Scand J Immunol; 2012 Sep; 76(3):320-8. PubMed ID: 22670785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ; Ji Q
    Transplant Proc; 2013; 45(1):153-6. PubMed ID: 23375290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells.
    Demirkiran A; Sewgobind VD; van der Weijde J; Kok A; Baan CC; Kwekkeboom J; Tilanus HW; Metselaar HJ; van der Laan LJ
    Transplantation; 2009 Apr; 87(7):1062-8. PubMed ID: 19352129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foxp3+ T cells in peripheral blood of renal transplant recipients and clinical correlations.
    Lin WX; Christiansen D; Fu LL; Roberts MA; Sandrin MS; Ierino FL
    Nephrology (Carlton); 2012 May; 17(4):415-22. PubMed ID: 22308996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
    Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.